Evidence map›Paper›PMID 36330713›Full record

ArticleEuropean journal of ophthalmology2022

The epidemiology of adults' eyelid malignancies in Germany between 2009 and 2015; An analysis of 42,710 patients' data.

Ahmad S Alfaar, C Nathanael Suckert, Matus Rehak, Christian Girbardt

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in European journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06080009 (Analysis of Molecular Biomarkers in Periocular Adnexal Tumours), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06080009 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Analysis of Molecular Biomarkers in Periocular Adnexal Tumours

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2023 to 2025Enrolled20ConditionsSebaceous Cell Tumor of EyelidArmsexome sequencing (retrospective) and exome and methylome sequencing (prospective)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ahmad S AlfaarDepartment of Ophthalmology, Universitätsklinikum Leipzig, Leipzig, Germany.ORCID 0000-0002-0930-4583
C Nathanael SuckertDepartment of Ophthalmology, Universitätsklinikum Leipzig, Leipzig, Germany.
Matus RehakDepartment of Ophthalmology, Universitätsklinikum Leipzig, Leipzig, Germany.
Christian GirbardtDepartment of Ophthalmology, Universitätsklinikum Leipzig, Leipzig, Germany.ORCID 0000-0002-7843-9617
University Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe report the incidence of malignant tumors of the eyelid in Germany between 2009 and 2015.

methodsData pertaining to the period between 2009 and 2015 were extracted from the German Cancer Registry. The International Classification of Diseases for Oncology-3 codes for tumors of the eyelid or canthus were used to identify incidence rates and survival probabilities. Crude and age-standardized incidence rates (ASR) were calculated by age, year, and gender and the individual federated states. Survival was calculated using the Kaplan-Meyer and Life tables methods, and COX-Regression was used to calculate hazard ratios for overall and cancer-specific survival.

resultsThis study examined data pertaining to 42,710 patients who had been diagnosed with malignant tumors of the eyelid. Basal cell carcinoma was by far the most common tumor of the eyelid (87.1%), followed by squamous cell carcinoma (10.1%) and malignant melanoma (1.1%). ASRs of basal cell carcinoma, squamous cell carcinoma, and melanoma were 65.1, 7.49, and 0.83 per million, respectively. Sebaceous cell carcinoma did not appear to be of high prevalence in Germany. Cancer-specific survival was generally high, exceeding 95%. The overall survival of patients with melanoma was considerably lower than those with other cancers. Both survival rates were inferior to that of basal cell carcinoma (74.9%). Cancer-Specific survival at five years for all groups exceeded 95%.

conclusionsThe incidence rates of malignant lid tumors match that of the European countries but shows a different pattern than Asian countries.

Indexed as

basal cell carcinomaepidemiologyEyelid malignanciesmelanomasquamous cell carcinoma

Identifiers

PMID36330713
PMCPMC9999282
OpenAlexW4308181907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.